1. Fraser D. Hypophosphatasia. Am J Med. 1957; 22(5):730-46.
2. Martin R, Fanaroff AA, Walsh MC. Fanaroff and Martin's neonatal-perinatal medicine. 10th ed. New York: Elsevier Health Sciences; 2014.
3. Kliegman RM, Stanton B, Schor N, Game J, Behrman R. Nelson textbook of pediatrics. 20th ed. New York: Elsevier Health Sciences; 2015.
4. Nishioka T, Tomatsu S, Gutierrez MA, Miyamoto K, Trandafirescu GG, Lopez PL, et al. Enhancement of drug delivery to bone: characterization of human tissuenonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab. 2006; 88(3):244-55.
5. Balasubramaniam S, Bowling F, Carpenter K, Earl J, Chaitow J, Pitt J, et al. Perinatal hypophosphatasia presenting as neonatal epileptic encephalopathy with abnormal neurotransmitter metabolism secondary to reduced co-factor pyridoxal-5'-phosphate availability. J Inherit Metab Dis. 2010; 33(Suppl 3): S25-33.
6. Gagnon C, Sims NA, Mumm S, McAuley SA, Jung C, Poulton IJ, et al. Lack of sustained response to teriparatide in a patient with adult hypophosphatasia. J Clin Endocrinol Metab. 2010; 95(3):1007-12.
7. Van den Bos T, Handoko G, Niehof A, Ryan LM, Coburn SP, Whyte MP, et al. Cementum and dentin in hypophosphatasia. J Dent Res. 2005; 84(11):1021-5.
8. Oda K, Kinjoh NN, Sohda M, Komaru K, Amizuka N. Tissue-nonspecific alkaline phosphatase and hypophosphatasia. Clin Calcium. 2014; 24(2):233-9.
9. Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012; 366(10):904-13.
10. Whyte MP, Rockman-Greenberg C, Ozono K, Riese R, Moseley S, Melian A, et al. Asfotase Alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol. 2015; 101(1):334-42.